{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["cf66dd7b-4193-4c3b-aad9-e8ec94cfa540", "Q2", 316731, "DAIICHI SANKYO, INC.", 185884, "DAIICHI SANKYO INC", 2017, "second_quarter", "2017-07-18T23:39:05.707000-04:00", 150000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/cf66dd7b-4193-4c3b-aad9-e8ec94cfa540/\", \"filing_uuid\": \"cf66dd7b-4193-4c3b-aad9-e8ec94cfa540\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2017, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/cf66dd7b-4193-4c3b-aad9-e8ec94cfa540/print/\", \"filing_document_content_type\": \"text/html\", \"income\": null, \"expenses\": \"150000.00\", \"expenses_method\": \"a\", \"expenses_method_display\": \"Method A - Reporting amounts using LDA definitions only\", \"posted_by_name\": \"Lance Gilgore\", \"dt_posted\": \"2017-07-18T23:39:05.707000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": \"United States of America\", \"registrant_address_1\": \"1825 K Street NW, Suite 425\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20006\", \"registrant\": {\"id\": 316731, \"url\": \"https://lda.senate.gov/api/v1/registrants/316731/\", \"house_registrant_id\": 39286, \"name\": \"DAIICHI SANKYO, INC.\", \"description\": null, \"address_1\": \"211 Mt Airy Rd\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"Basking Ridge\", \"state\": \"NJ\", \"state_display\": \"New Jersey\", \"zip\": \"07920\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"AMANDA PEZALLA\", \"contact_telephone\": \"+1 202-223-6572\", \"dt_updated\": \"2026-01-23T12:14:15.149771-05:00\"}, \"client\": {\"id\": 185884, \"url\": \"https://lda.senate.gov/api/v1/clients/185884/\", \"client_id\": 12, \"name\": \"DAIICHI SANKYO INC\", \"general_description\": null, \"client_government_entity\": false, \"client_self_select\": true, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"DC\", \"ppb_state_display\": \"District of Columbia\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2007-08-13\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"Discussions regarding the Affordable Health Care Act (ACA)\\nH.R.1703, Medical Product Communications Act of 2017\", \"foreign_entity_issues\": \"To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 6903, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"LANCE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GILGORE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"Discussions regarding Medicare\", \"foreign_entity_issues\": \"To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 6903, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"LANCE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GILGORE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}]}, {\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017\\nH.R.2430 and S.934, FDA Reauthorization Act of 2017\", \"foreign_entity_issues\": \"To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 6903, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"LANCE\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GILGORE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["cf66dd7b-4193-4c3b-aad9-e8ec94cfa540"], "units": {}, "query_ms": 21.229506004601717, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}